Enrico Heffler

Dr. Enrico Heffler

Department of Biomedical Sciences – Humanitas University – Via Rita Levi Montalcini 4, 20090 – Pieve Emanuele (MI), Italy
+1
orcid

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2019 in Allergy
Verified
Journal Article
Open access
PDF file
WFWytske J. Fokkens
Wytske J. Fokkens
VLValerie Lund
Valerie Lund
CBClaus Bachert
Claus Bachert
JMJoaquim Mullol
Joaquim Mullol
LBLeif Bjermer
Leif Bjermer
PHPeter W. Hellings
Peter W. Hellings
Novel therapies such as type 2 targeting biologics are emerging treatment options for patients with chronic inflammatory respiratory diseases, fulfilling the needs of severely uncontrolled patients. The majority of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with asthma show a type 2 inflammatory signature in sinonasal mucosa and/or lungs. Importantly, both chronic respiratory diseases are frequent comorbidities, ensuring alleviation of both upper and lower airway pathology by systemic biological therapy. Type 2‐targeting biologics such as anti‐IgE, anti‐IL4Rα, anti‐IL5, and anti‐IL5Rα have entered the market for selected pheno/endotypes of asthma patients and may soon also become available for CRSwNP patients. Given the high prevalence of chronic respiratory diseases and the high cost associated with biologics, patient selection is crucial in order to implement such therapies into chronic respiratory disease care pathways.The European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) organized a multidisciplinary Expert Board Meeting to discuss the positioning of biologics into the care pathways for CRSwNP patients with and without comorbid asthma.

17 December 2019 in Frontiers in Physiology
Verified
Journal Article
Open access
Corrado PelaiaCorrado Pelaia
Corrado Pelaia
Giovanni PaolettiGiovanni Paoletti
Giovanni Paoletti
FPFrancesca Puggioni
Francesca Puggioni
FRFrancesca Racca
Francesca Racca
GPGirolamo Pelaia
Girolamo Pelaia
Enrico HefflerEnrico Heffler
Enrico Heffler
Interleukin-5 (IL-5) exerts a central pathogenic role in differentiation, recruitment, survival and degranulation of eosinophils. Indeed, during the last years significant advances have been made in our understanding of the cellular and molecular mechanisms underlying the powerful actions of IL-5 finalized to the induction, maintenance and amplification of eosinophilic inflammation. Therefore, IL-5 is a suitable target for add-on biological therapies based on either IL-5 inhibition (mepolizumab, reslizumab) or blockade of its receptor (benralizumab). These modern treatments can result to be definitely beneficial for patients with severe type 2 (T2)-high eosinophilic asthma, refractory to conventional anti-inflammatory drugs such as inhaled and even systemic corticosteroids.

23 August 2022 in Allergy
Verified
Journal Article
Open access
Gilda VarricchiGilda Varricchi
Gilda Varricchi
SFSebastian Ferri
Sebastian Ferri
JPJack Pepys
Jack Pepys
Remo PotoRemo Poto
Remo Poto
GSGiuseppe Spadaro
Giuseppe Spadaro
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica
Asthma is a chronic inflammatory airway disease resulting in airflow obstruction, which in part can become irreversible to conventional therapies, defining the concept of airway remodeling. The introduction of biologics in severe asthma has led in some patients to the complete normalization of previously considered irreversible airflow obstruction. This highlights the need to distinguish a “fixed” airflow obstruction due to structural changes unresponsive to current therapies, from a “reversible” one as demonstrated by lung function normalization during biological therapies not previously obtained even with high‐dose systemic glucocorticoids. The mechanisms by which exposure to environmental factors initiates the inflammatory responses that trigger airway remodeling are still incompletely understood. Alarmins represent epithelial‐derived cytokines that initiate immunologic events leading to inflammatory airway remodeling. Biological therapies can improve airflow obstruction by addressing these airway inflammatory changes. In addition, biologics might prevent and possibly even revert “fixed” remodeling due to structural changes. Hence, it appears clinically important to separate the therapeutic effects (early and late) of biologics as a new paradigm to evaluate the effects of these drugs and future treatments on airway remodeling in severe asthma.

1 May 2018 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
Enrico HefflerEnrico Heffler
Enrico Heffler
LMLorena Nascimento Girardi Madeira
Lorena Nascimento Girardi Madeira
MFMatteo Ferrando
Matteo Ferrando
Francesca PuggioniFrancesca Puggioni
Francesca Puggioni
FRFrancesca Racca
Francesca Racca
Giorgio Walter CanonicaGiorgio Walter Canonica
Giorgio Walter Canonica

6 April 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
ZDZuzana Diamant
Zuzana Diamant
SVSusanne J.H. Vijverberg
Susanne J.H. Vijverberg
KAKjell Alving
Kjell Alving
ABArzu Bakirtas
Arzu Bakirtas
LBLeif Bjermer
Leif Bjermer
SSSven F. Seys
Sven F. Seys

1 May 2019 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
Enrico HefflerEnrico Heffler
Enrico Heffler
Francesco BlasiFrancesco Blasi
Francesco Blasi
MLManuela Latorre
Manuela Latorre
FMFrancesco Menzella
Francesco Menzella
PPPierluigi Paggiaro
Pierluigi Paggiaro
GSGiuseppe Spadaro
Giuseppe Spadaro